肝硬化血氨测定的国际德尔菲共识:ISHEN推荐意见
该共识就血氨作为生物标志物的临床意义、样本采集与分析最佳实践、风险分层、治疗监测及预后判断作用提出推荐,并指出床旁检测、风险模型验证等研究缺口。
要点
- 共识推荐规范血氨样本采集与分析,以 harmonize 临床实践。
- 血氨可用于预测显性肝性脑病及其他肝脏相关并发症。
- 血氨在显性肝性脑病的诊断与预后判断中具有作用。
核心结论
- ISHEN首部国际循证共识明确了血氨测定在肝硬化患者诊疗中的角色。
- 共识为临床医生提供实践推荐,并列出未来研究优先方向。
研究设计与样本
- 采用改良德尔菲法,写作委员会11名专家,专家组39名成员由ISHEN基于专业、全球代表性和性别平衡选出。
主要发现
- 专家组对所有问题达成≥90%共识,涵盖血氨作为生物标志物在住院和门诊环境中的临床意义。
- 共识涵盖样本采集与分析最佳实践,以及血氨在风险分层、治疗监测和预后判断中的作用。
- 识别出的研究缺口包括床旁血氨检测需求、血氨风险模型验证及非高氨性脑病更好表征。
临床怎么用
- 共识提供血氨测量与报告方式的实践指导,有助于全球实践一致化。
- 血氨测定可用于预测显性肝性脑病及其他肝脏相关并发症。
- 血氨测定在显性肝性脑病的诊断和预后判断中具有作用。
局限性
- 原文指出血氨测定的临床效用因方法学变异、解读不一致和缺乏标准化指导而存在争议。
- 研究缺口包括床旁血氨检测、血氨风险模型验证及非高氨性脑病表征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Ammonia is a neurotoxin implicated in the pathogenesis of hepatic encephalopathy (HE). Yet, the clinical utility of blood ammonia measurement in patients with cirrhosis remains controversial due to methodological variability, inconsistent interpretation, and lack of standardised guidance. The aim of this consensus document, developed by the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN), is to provide evidence-based recommendations on the role of ammonia measurement in the diagnosis, monitoring, and treatment of patients with cirrhosis. METHODS: A modified Delphi process was conducted involving a multidisciplinary and international panel of experts in cirrhosis and ammonia metabolism. The writing committee comprised 11 experts, and the panel included 39 members selected by ISHEN based on expertise, global representation, and gender balance. Twenty-five PICO questions were generated. Following literature review and based on the level of evidence, recommendations and statements were formulated. The questions, recommendations, and statements underwent approval across four Delphi rounds. RESULTS: The panel reached ≥90% consensus on all the questions, including the clinical significance of ammonia as a biomarker in both inpatient and outpatient settings, best practices for sample collection and analysis, and the role of ammonia in risk stratification, therapeutic monitoring, and prognostication. Specific research gaps were identified, including the need for point-of-care ammonia testing, validation of ammonia-based risk models and better characterisation of non-hyperammonemic encephalopathy. CONCLUSIONS: This ISHEN consensus is the first structured international effort to define the role of ammonia measurement in the care of patients with cirrhosis. It offers practical recommendations for clinicians, outlines priorities for future research, and provides a foundation for harmonizing clinical practice and trial design related to ammonia and HE. IMPACT AND IMPLICATIONS: This is the first international, evidence-based consensus describing the role of ammonia measurement in patients with cirrhosis. The consensus details guidance on how to measure ammonia, the role of ammonia measurement in predicting development of overt hepatic encephalopathy and other liver-related complications, and its role in the diagnosis and prognosis of patients with overt hepatic encephalopathy. This document will help harmonise practices across the world in the way ammonia should be measured and reported, impacting significantly on patient outcomes, research and drug development efforts.
引用
- Ballester MP, Gallego-Durán R, Shalimar, et al. Ammonia measurement in cirrhosis: International Delphi consensus recommendations from ISHEN. J Hepatol. 2026. PMID: 41865800. doi:10.1016/j.jhep.2026.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。